Q2 21: Marginal beat not good enough
29/07/21 -"Smith & Nephew reported consensus beating Q2 21 sales growth of 40.3%, thanks to a strong recovery in Orthopaedics (+43.4%) and ‘sports medicine & ENT’ (+50.9%). Regionally, growth was driven ..."
Pages
60
Language
English
Published on
29/07/21
You may also be interested by these reports :
13/05/24
DiaSorin started 2024 on a promising note with sales and profitability exceeding expectations. Healthy growth across segments was offset by waning ...
10/05/24
While the 2023 EPS benefitted from material deferred tax income, we have moderated our earnings estimates for 2024-25 owing to high interest rates ...
10/05/24
Fresenius reported Q1 figures that exceeded the consensus, with revenues increasing by 0.3%, adjusted EBIT by 4.5%, net income from continuing ...
09/05/24
Smith & Nephew reported marginally softer than expected Q1 24 numbers. The weakness was largely attributable to US implants and areas within wound ...